<DOC>
	<DOCNO>NCT01909466</DOCNO>
	<brief_summary>To determine safety tolerability multiple-dose administration aripiprazole intramuscular ( IM ) depot deltoid muscle adult subject schizophrenia</brief_summary>
	<brief_title>Safety Tolerability Study Aripiprazole IM Depot Adult Subjects With Schizophrenia</brief_title>
	<detailed_description>This trial design assess safety tolerability multiple-dose administration aripiprazole intramuscular ( IM ) depot deltoid muscle adult subject schizophrenia . The trial consist 113 day treatment period 28 day followup . The trial population include male female subject 18 64 year ( inclusive ) , current diagnosis schizophrenia define DSM-IV-TR criterion prior history tolerate aripiprazole per investigator 's judgement .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Male female individual 18 64 year , inclusive , time informed consent . Prior history tolerate aripiprazole per investigator 's judgement . Subjects meet DSMVIVTR criterion substance dependence within past 180 day . Subjects use one antipsychotic medication screening . Use CYP2D6 CYP3A4 inhibitor , CYP3A4 inducer within 14 day prior dose duration trial . Subjects participate clinical trial involve psychotropic medication within 1 month prior enrollment . Subjects currently acute relapse schizophrenia . Subjects current DSMVIVTR diagnosis schizophrenia . Subjects consider treatmentresistant antipsychotic medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>OPC-14597</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>